• search hit 1 of 2
Back to Result List

18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation

Please always quote using this URN: urn:nbn:de:bvb:20-opus-113107
  • The aim of this study was to investigate the prognostic value of 18F-fluoro-deoxyglucose positron emission tomography–computed tomography (18F-FDG-PET/CT) in 37 patients with a history of multiple myeloma (MM) and suspected or confirmed recurrence after stem cell transplantation (SCT). All patients had been heavily pre-treated. Time to progression (TTP) and overall survival (OS) were correlated to a number of different PET-derived as well as clinical parameters. Impact on patient management was assessed. Absence of FDG-avid MM foci was aThe aim of this study was to investigate the prognostic value of 18F-fluoro-deoxyglucose positron emission tomography–computed tomography (18F-FDG-PET/CT) in 37 patients with a history of multiple myeloma (MM) and suspected or confirmed recurrence after stem cell transplantation (SCT). All patients had been heavily pre-treated. Time to progression (TTP) and overall survival (OS) were correlated to a number of different PET-derived as well as clinical parameters. Impact on patient management was assessed. Absence of FDG-avid MM foci was a positive prognostic factor for both TTP and OS (p<0.01). Presence of >10 focal lesions correlated with both TTP (p<0.01) and OS (p<0.05). Interestingly, presence of >10 lesions in the appendicular skeleton proved to have the strongest association with disease progression. Intensity of glucose uptake and presence of extramedullary disease were associated with shorter TTP (p=0.037 and p=0.049, respectively). Manifestations in soft tissue structures turned out to be a strong negative predictor for both, TTP and OS (p<0.01, respectively). PET resulted in a change of management in 30% of patients. Our data underline the prognostic value of 18F-FDG-PET/CT in MM patients also in the setting of post-SCT relapse. PET/CT has a significant impact on patient management.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Katharina Lückerath, Constantin Lapa, Uwe Malzahn, Samuel Samnick, Herrmann Einsele, Andreas K. Buck, Ken Herrmann, Stefan Knop
URN:urn:nbn:de:bvb:20-opus-113107
Document Type:Journal article
Faculties:Medizinische Fakultät / Institut für Medizinische Strahlenkunde und Zellforschung
Medizinische Fakultät / Medizinische Klinik und Poliklinik II
Medizinische Fakultät / Institut für Klinische Epidemiologie und Biometrie
Language:English
Year of Completion:2014
Source:OncoTarget 5 (2014),17, S. 7381-7391
Sonstige beteiligte Institutionen:Clinical Trial Center (CTC) / Zentrale für Klinische Studien Würzburg (ZKSW)
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:18FDG-PET/CT; FDG-PET/CT; Multiple myeloma; molecular imaging
Release Date:2015/05/19
Collections:Open-Access-Publikationsfonds / Förderzeitraum 2014
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung